← SynDRA
VANDETANIB
SynDRA canonical compound SYN0001517 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx/OTC |
|---|
| Primary target(s) | TEK |
|---|
| Mechanism of action | RET tyrosine kinase inhibitor |
|---|
| Indication | medullary thyroid cancer (MTC) |
|---|
| Disease area | oncology |
|---|
All known targets
- KDR
- RET
- EGFR
- PTK6
- FLT4
- FLT1
- TEK
- EPHA7
- EPHA2
- EPHA3
- EPHA4
- EPHA5
Mechanisms of action (all sources)
- EGFR INHIBITOR
- VEGFR inhibitor
- RET tyrosine kinase inhibitor
- SRC inhibitor
- Tyrosine-protein kinase SRC inhibitor
- PTK6 INHIBITOR
- Tyrosine-protein kinase BRK inhibitor
- TEK INHIBITOR
- Tyrosine-protein kinase TIE-2 inhibitor
- FLT1 INHIBITOR
- Vascular endothelial growth factor receptor inhibitor
- FLT4 INHIBITOR
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- HRH3
- SYK
- KCNH2
- SLC6A4
- LRRK2
- CHRNA4
- MTOR
- ADRA2C
- ADRA2B
- ADRA2A
- AURKB
- HRH1
- NR1I2
- PAK2
- PDE4D
- OPA1
- PGRMC1
- OPRD1
- PGR
- OPRK1
- PEBP1
- PDXK
- PDPK1
- OPRM1
- PAK3
- PDE3A
- OXSR1
- PAICS
- PAK1
- PASK
- PAK6
- PAK5
- PAK4
- PCYT1A
- PIK3CA
- PI4KB
- PIK3C2B
- PRKACB
- PRKACA
- PRKAA2
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
- ACVL1
- ATXN2
- TNI3K
- PNMT
- PGFRB
- PGFRA
- NTMT1
- NTM1A
- NSD2
- NNMT
- MRCKG
- MP2K2
- MP2K1
- MK14
- MK06
- M4K5
- M4K4
- M4K3
- KSYK
- KS6A6
- KS6A1
- KIF5B
- KC1E
- HNMT
- GNMT
- GEMI
- GAMT
- CTRO
- CP1A2
- COMT
- CCDC6
- TP53
Drug classes
- Protein Kinase Inhibitors
- Kinase Inhibitor
- P-Glycoprotein Inhibitors
- Organic Cation Transporter 2 Inhibitors
ATC classes
- L01E · PROTEIN KINASE INHIBITORS
Cross-references
Synonyms
- CAPRELSA
- Caprelsa
- ZD-6474
- zactima
- caprelsa
- ZD6474
- GNF-PF-2188
- NSC-744325
- NSC-760766
- ZD-64
- Zactima
- Vandetanib [INN]
- CH-331
- AZD-6474
- F9995-0087
- Zactima, ZD6474
- Vandetanib (JAN/INN)
- Vandetanib, Zactima, ZD6474
- Vandetanib (Pan-TK inhibitor)
- vandetanib (zd6474)
- ZD 6474
- NSC 744325
- NSC 760766
- CHEMBL24828
- YO460OQ37K
- CHEBI:49960
- MFCD07772346
- NCGC00167513-01
- CAS-443913-73-3
- UNII-YO460OQ37K
- Vandetinib
- HSDB 8198
- 2ivu
- Vandetanib [USAN:INN:BAN:JAN]
- Caprelsa (TN)
- Vandetanib- Bio-X
- Vandetanib (Zactima)
- DMPC Cyclic Urea 1
Reported adverse events
- Torsades de pointes
- Acne
- Alopecia
- Colitis
- Depression
- Dermatitis
- Dysgeusia
- Dyspepsia
- Fatigue
- Headache
- Hypertension
- Hypothyroidism
Look up VANDETANIB in the interactive SynDRA portal →